Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: John William Anderson who wrote (1750)	2/10/2004 8:12:04 PM
From: Art Bechhoefer	Read Replies (1) \| Respond to of 1870

Apparently Genasense is effective on cancers other than melanoma. If the FDA gives approval, as is likely, then the drug may be prescribed for other cancers as well, even though the clinical tests were limited to melanoma. A characteristic of antisense drugs as a group is that they seem to reduce autoimmune responses to traditional chemotherapy treatment, making it possible to lower the dosage or improve long term effectiveness when traditional chemo is combined with antisense drugs. I'll be interested to see if GNTA is still financially viable on the basis of the latest financial report to be issued tomorrow. Art